What is PET imaging and how is it used?
- Positron Emission Tomography (PET) imaging is a non-invasive diagnostic technique used to visualise biological processes in the brain. In Alzheimer’s disease, PET imaging enables the detection of key pathological changes associated with the condition.
- There are three main types of PET imaging used in Alzheimer’s care:
- Amyloid PET – identifies amyloid plaque accumulation
- Tau PET – detects tau protein tangles
- FDG-PET – measures glucose metabolism as an indicator of neuronal activity
PET imaging is used in clinical practice to:
- Support the diagnosis of Alzheimer’s disease, particularly in uncertain or complex cases
- Differentiate Alzheimer’s disease from other types of dementia
- Provide biological confirmation of disease pathology
- Guide treatment decisions, including eligibility for disease-modifying therapies
- Support clinical trial selection and monitoring
- As Alzheimer’s disease definitions increasingly incorporate biomarkers, PET imaging is becoming a key component of specialist diagnostic pathways.
Key insights
- PET imaging enables earlier detection of Alzheimer’s-related brain changes before significant clinical decline
- Biomarker-led diagnosis is evolving, with amyloid and tau PET central to emerging frameworks
- Different PET modalities provide complementary information, supporting more precise diagnosis
- Use is most appropriate in selected patients, particularly when diagnosis is uncertain
- Integration into practice requires expertise, including correct interpretation and adherence to guidelines
- These insights reflect a broader shift towards precision medicine in Alzheimer’s disease.
What are the aims of the independent medical education program on PET imaging?
This independent medical education (IME) program aims to equip healthcare professionals with the knowledge and confidence to appropriately integrate PET imaging into Alzheimer’s care.
The core aims are to:
- Build foundational knowledge
Understand how PET imaging works and the role of different tracers (amyloid, tau, FDG) - Support clinical decision-making
Clarify when PET imaging is appropriate and how it informs diagnosis and management - Improve interpretation skills
Strengthen understanding of imaging results within real-world clinical contexts - Align with best practice and guidelines
Highlight current recommendations, appropriate use criteria, and evolving standards - Enhance patient-centred care
Enable earlier, more accurate diagnoses and better-informed discussions with patients and caregivers
What can I expect to get from this independent medical education program?
This program is designed to deliver practical, clinically relevant learning that can be directly applied in practice.
You will gain:
- A clearer understanding of PET imaging
- How PET imaging works and its role in Alzheimer’s disease
- Differences between amyloid, tau, and FDG PET
- Practical clinical insights
- When to use PET imaging in real-world scenarios
- How to interpret results in the context of other diagnostic tools
- Confidence in decision-making
- Greater ability to integrate PET imaging into diagnostic pathways
- Improved confidence when discussing imaging with patients and multidisciplinary teams
- Up-to-date knowledge
- Insights into current evidence, evolving biomarkers, and best practice guidance
- Improved patient management
- Tools to support more accurate diagnosis
- Better-informed treatment planning and care strategies
Frequently asked questions about PET imaging in Alzheimer’s disease
- What is PET imaging and when is it used in Alzheimer’s disease?
PET imaging is used when there is diagnostic uncertainty, helping to confirm or rule out Alzheimer’s pathology through detection of amyloid or tau. - What is the difference between amyloid PET, tau PET, and FDG-PET?
Amyloid PET detects plaque buildup, tau PET identifies neurofibrillary tangles, and FDG-PET measures brain metabolism. - How accurate is PET imaging for Alzheimer’s disease?
PET imaging is highly sensitive for detecting Alzheimer’s biomarkers, particularly amyloid, but should be interpreted alongside clinical assessment. - How does PET imaging complement MRI or other tests?
PET provides functional and molecular information, while MRI shows structural changes—together they improve diagnostic accuracy. - When should PET imaging be used in clinical practice?
It is most appropriate in cases of diagnostic uncertainty, early-onset dementia, or atypical presentations.